Bruce Roberts

Managing Director

Managing Director at RM Global (US Office), Bruce holds over 25 years of international banking, strategic, and investment experience in the life sciences sector. In addition to biopharma, he has specific expertise in medical technology and drug-device combination products.

Bruce has dedicated his career to the mission of RM Global, having co-founded the business under RMG’s predecessor firm Roberts Mitani in the early 1990’s. He has completed multiple innovative transactions in the life sciences space for clients including Micrus Endovascular (acquired by JNJ), Encysive Pharmaceuticals (acquired by Pfizer), Anterios (acquired by Allergan) and MediBeacon, among many others, and has advised on life science investment strategies for corporate clients including Toyota, AmorePacific Group, and Cosmotec. He is a General Partner of the RMGP Bio-Pharma Investment Fund, which is deploying approximately $65 million into innovative biopharma start-ups in Israel in collaboration with JNJ, Takeda, Bayer and Orbimed. He also is the manager of Select Medical Opportunities Management, LLC, which is structuring special purpose investment vehicles focused on medtech.

Bruce is a member of the board of directors and Chairman of the Audit Committee of Healthcare Capital Corp. (NASDAQ:HCCCU), a publicly traded special purpose acquisition company which raised $275 million in 2021 to build a major healthcare enterprise. He is also Chairman of Nectero Medical, a company developing treatments for vascular aneurysm disease, a board member of Control Medical Technology, a company commercializing novel blood clot management devices, and a managing partner of Health Family Capital, LLC, a family office focused on private healthcare investing. He serves on the national board of directors of AdvaMed Accel, the emerging company arm of the leading trade association for U.S. medical technology companies.

Prior to his banking and asset management career, Bruce was an owner and director of Flori Roberts, a successful consumer skin care company sold to Ivax Pharmaceuticals, and practiced corporate and securities law with Sidley Austin, one of the leading law firms in the U.S.

His past directorships also include Endologix, a U.S. device company focused on aneurysm treatment; Devax, a U.S. coronary stent company (sold to Biosensors); BioEnterprise, a regional bio accelerator; and Global Biomedical Partners AG, a Swiss based biomedical-focused private equity fund management company (sold to HBM Bioventures). He has also lectured on private equity at the Executive MBA program of the NYU Stern School of Business and served as a judge for the Genesis Generation Challenge, an initiative of the Genesis Prize Foundation. Bruce received an A.B. in History and Government from Harvard College, summa cum laude, and a J.D. from Harvard Law School.